Difference between revisions of "Motesanib (AMG-706)"
Jump to navigation
Jump to search
m |
m |
||
Line 20: | Line 20: | ||
[[Category:RET inhibitors]] | [[Category:RET inhibitors]] | ||
− | [[Category:Thyroid cancer medications (investigational)]] | + | [[Category:Thyroid cancer, differentiated medications (investigational)]] |
[[Category:Halted drugs]] | [[Category:Halted drugs]] |
Revision as of 12:30, 25 December 2022
Mechanism of action
From the NCI Drug Dictionary: The orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. Motesanib selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors
Preliminary data
Thyroid cancer
- Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 3;359(1):31-42. link to original article PubMed
Also known as
- Code name: AMG 706